Back to REGN Overview
NMS · Valuation Lab
REGN
Regeneron Pharmaceuticals, Inc.
Last$768.58
Market cap79.1B
EV/EBITDA15.0x
Intrinsic value
$2120.96
MoS +63.8% · Undervalued
Assuming 19.7% FCF margin and 16.7% Y1–5 growth.
Upside to price
EV (DCF)209.2B
Terminal share77%
Expected IV$2081.32
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 77% of EV
PV of stage FCFs47.1B
PV of terminal value162.1B
Enterprise value209.2B
Net cash / (debt)5.3B
Equity value214.5B
Intrinsic value / share$2120.96
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 18.1B | 3.6B | 3.4B | 94.3% |
| Y2 | 21.2B | 4.2B | 3.7B | 89.0% |
| Y3 | 24.7B | 4.9B | 4.1B | 84.0% |
| Y4 | 28.8B | 5.7B | 4.5B | 79.2% |
| Y5 | 33.6B | 6.6B | 4.9B | 74.7% |
| Y6 | 36.4B | 7.2B | 5.1B | 70.5% |
| Y7 | 39.5B | 7.8B | 5.2B | 66.5% |
| Y8 | 42.8B | 8.4B | 5.3B | 62.7% |
| Y9 | 46.4B | 9.1B | 5.4B | 59.2% |
| Y10 | 50.3B | 9.9B | 5.5B | 55.8% |
| Terminal | — | — | 162.1B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.